Zacks Analyst Blog Highlights: Motorola Solutions, Nokia, Siemens AG, Stryker and Boston Scientific

CHICAGO, Jan. 25, 2011 /PRNewswire/ -- Zacks.com Analyst Blog features: Motorola Solutions Inc. (NYSE: MSI), Nokia Corp. (NYSE: NOK), Siemens AG (NYSE: SI), Stryker Corporation (NYSE: SYK) and Boston Scientific (NYSE: BSX).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Monday's Analyst Blog:

Neutral on Motorola Solutions

We initiate coverage on Motorola Solutions Inc. (NYSE: MSI) with a Neutral recommendation. Motorola Solutions is a market leader in the lucrative Public Safety market. Several industry researchers estimate that the market size of Public Safety may reach $6.5 billion in 2014.

Most of the products of Motorola Solutions are based on the state-of-the art wireless broadband mobility solutions architecture of the former Motorola Inc. We believe the company will maintain its current top-line growth in future primarily due to an improving global economy that will sustain both government and enterprise spending.

Motorola Solutions caters to a large set of industries including Transportation & Logistics, Hospitality, Public Safety, Retail, Wholesale Distribution, Oil & Natural Gas, Utilities, to name a few. After the spin-off, the company has a solid net cash position of $2.7 billion.

Recently, Standard & Poor's Rating Services raised its corporate credit and senior unsecured ratings on Motorola Solutions to "BBB" from "BB+". Fitch Rating also upgraded the company's long-term issuer default rating to "BBB" from "BBB-" and provided a stable outlook.

The strong cash balance of the company will further get boosted once Nokia Siemens Networks, a joint venture between Nokia Corp. (NYSE: NOK) and Siemens AG (NYSE: SI) completes its proposed acquisition of the wireless infrastructure businesses of Motorola Solutions.

This includes all of GSM, CDMA, and WCDMA networks as well as 4G WiMAX and LTE networks. Motorola will receive $1.35 billion from this deal including $1.2 billion from Nokia Siemens Networks and the rest $150 million from retained accounts receivables. The deal is expected to close by the first quarter of 2011.

Nevertheless, Motorola Solutions is heavily dependent on Government expenditures for its revenue. Approximately 65% of total sales of Motorola Solutions comes from government agencies. Although we do not suspect any near-term dip in government expenditures, we remain concerned that any macro-economic fluctuations may make the company's top-line volatile.

Earnings Preview: Stryker

Orthopedic devices giant Stryker Corporation (NYSE: SYK) is expected to release its fourth quarter and fiscal 2010 results on January 25, after the closing bell. The Michigan-based company announced, on January 10, encouraging preliminary sales data for the quarter and fiscal year, which beat the Zacks Consensus Estimates. Revenues for both fourth quarter and fiscal 2010 grew nearly 9% to $2 billion and $7.32 billion, respectively.

Global Orthopedic Implants sales grew 4.5% in the fourth quarter reflecting signs of recovery in this business. Hips, knees and trauma franchises posted growth in the quarter while the spine business continued to disappoint. Worldwide revenues for MedSurg Equipment, Stryker's growth business, soared roughly 15% in the quarter.

Stryker raised its adjusted earnings guidance for fiscal 2010, which it now envisions to range between $3.31 and $3.33 a share compared to the earlier view of $3.27 and $3.30. Moreover, the company has released a buoyant outlook for fiscal 2011. The current Zacks Consensus Estimates for fourth quarter and fiscal 2010 are 90 cents and $3.31, respectively.

Third-Quarter Flashback

Stryker posted better-than-expected third quarter 2010 results with earnings of 80 cents per share surpassing the Zacks Consensus Estimate of 77 cents. Net income jumped 47.5% year over year led by sustained healthy sales from the MedSurg division.

Revenues grew 6.9% year over year to $1,768 million, also exceeding the Zacks Consensus Estimate of $1,749 million. However, strong growth at MedSurg was partly masked by yet another sluggish performance by the core Orthopedic division due to weak spine and knees sales.

Stryker's domestic sales benefited in the quarter from higher shipments of orthopedic implants and surgical equipment while international revenue growth was muted on account of an unfavorable foreign exchange translation effect.

Estimate Revisions Trend

Agreement

Earnings estimates for fourth-quarter 2010 have been static over the past week with no movements in either direction. However, there has been a clear upswing over the last 30 days, mostly attributable to the strong preliminary sales and the company's upbeat guidance.

Out of 27 analysts covering the stock, 11 have raised their estimates over the past month with just 1 moving in the opposite direction, manifesting a strong directional consensus. The analysts are expecting Stryker to outperform based on the solid revenue performance.

Similarly, for fiscal 2010, 13 out of 21 analysts have hiked their forecasts over the last 30 days while 1 lowered his/her estimate. There has been a solitary positive revision over the past 7 days with no reverse movements.

Magnitude

The magnitude of revisions for the forthcoming quarter and fiscal year has been torpid over the last week. However, a plethora of upward estimate revisions accompanied by a sheer directional pressure have led to an increase in the estimates for the fourth quarter and fiscal 2010 by 1 cent and 2 cents, respectively, over the past 30 days.

With respect to earnings surprises, Stryker has posted two positive surprises in the preceding four quarters while it met the Zacks Consensus Estimates on two other occasions. The company has produced an average positive earnings surprise of 3.23% over the last four quarters, implying that it has beat the Zacks Consensus Estimate by that measure.

Neutral on Stryker

Stryker is one of the world's largest medical devices companies with a well-diversified product portfolio. It continues to expand its product range by acquiring complementary products/businesses. Stryker remains well positioned for growth across its Orthopedic and MedSurg units driven by new product launches, acquisitions and an improving hospital capital spending backdrop.

The company's MedSurg division continues to grow at a healthy double-digit rate, benefiting from the synergies of the acquisition of Ascent Healthcare. The MedSurg business continues to show resilience in a still challenging macroeconomic backdrop.

With the sale of its bone growth product franchise ("OP-1" product line) to Tokyo-based equipment manufacturer Olympus Corporation, Stryker plans to redirect a part of the related R&D spending to other internal projects, which it believes has the potential to deliver better returns.

Moreover, Stryker remains committed to delivering incremental returns to investors leveraging its solid balance sheet, healthy free cash flow and earnings power. The company, in December 2010, raised its quarterly dividend by 20% and announced an additional $500 million share repurchase program.

Stryker recently unfolded an optimistic outlook for fiscal 2011 with revenues expected to grow 11-13% in constant currency on the back of higher shipments of Orthopedic Implants and MedSurg Equipment coupled with the contribution from its recently acquired neurovascular business of Boston Scientific (NYSE: BSX).

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5514.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5516

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks InvestmentResearch is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.